Recent report – Drug Development Opportunities in China: Regulation, key players and initiatives for domestic and international markets by report linker reveals that China has emerged as an increasingly attractive option for companies aiming to reduce such prohibitive investments in time and finance.
Drug developments in the US and EU are becoming increasingly expensive and time consuming, with new products typically requiring investment of over 4 years and $1billion from concept to commercialization. As a result, China has emerged as an increasingly attractive option for companies aiming to reduce such prohibitive investments in time and finance.
Human clinical studies have historically dominated outsourced R&D activities in China, with the country’s relative lack of capital and expertise being insufficient to facilitate technologically intensive discovery and pre-clinical work. However, an influx of western-trained scientists and increasing access to global capital markets are rapidly extending the development opportunities available to China’s expanding base of pharma and biotech companies.
China’s drug development industry, both in terms of expanding domestic markets and the country’s role as a third-party provider of outsourced global drug developments.